Group 1 - Zacks Premium offers various tools for investors, including daily updates on Zacks Rank and Industry Rank, access to the Zacks 1 Rank List, Equity Research reports, and Premium stock screens to enhance investment confidence [1][2] - The Zacks Style Scores rate stocks based on value, growth, and momentum characteristics, providing complementary indicators to the Zacks Rank [2][3] Group 2 - The Value Score identifies attractive and discounted stocks using ratios like P/E, PEG, and Price/Sales, appealing to value investors [3] - The Growth Score focuses on a company's financial strength and future outlook, analyzing projected and historic earnings, sales, and cash flow [4] - The Momentum Score helps investors capitalize on price trends by examining one-week price changes and monthly earnings estimate changes [5] Group 3 - The VGM Score combines all Style Scores, offering a comprehensive indicator for investors who utilize multiple investing styles [6] - The Zacks Rank employs earnings estimate revisions to simplify portfolio building, with 1 (Strong Buy) stocks achieving an average annual return of +23.62% since 1988, outperforming the S&P 500 [7][9] Group 4 - Eli Lilly and Company, a major pharmaceutical firm, has a diversified product profile and a strong pipeline in obesity, diabetes, and Alzheimer's [11] - Eli Lilly holds a Zacks Rank of 3 (Hold) with a VGM Score of A and a Growth Style Score of B, indicating a forecasted year-over-year earnings growth of 69.3% for the current fiscal year [11][12] - Recent upward revisions in earnings estimates and an average earnings surprise of +6.7% further enhance Eli Lilly's attractiveness to growth investors [12]